Stay updated on Pembrolizumab in 1st Line NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in 1st Line NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in 1st Line NSCLC Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The update appears to be limited to minor UI/layout adjustments and an updated last update date; the core content (title, conditions, trial arms, eligibility criteria, and outcomes) remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-03T01:00:08.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    33 days ago
    Change Detected
    Summary
    Major change: version bump to v3.2.0 and an important operating-status notice about government funding and NIH Clinical Center, directing users to official sources.
    Difference
    2%
    Check dated 2025-10-05T09:25:20.000Z thumbnail image
  4. Check
    40 days ago
    Change Detected
    Summary
    Version bump from v3.0.2 to v3.1.0; no other content changes detected.
    Difference
    0.1%
    Check dated 2025-09-28T03:07:24.000Z thumbnail image
  5. Check
    55 days ago
    Change Detected
    Summary
    Revision updated from v3.0.1 to v3.0.2; removed the 'Back to Top' element.
    Difference
    0.1%
    Check dated 2025-09-13T16:55:14.000Z thumbnail image
  6. Check
    62 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.
    Difference
    0.1%
    Check dated 2025-09-06T14:20:48.000Z thumbnail image
  7. Check
    69 days ago
    Change Detected
    Summary
    The web page has been updated to include new drug information for various compounds, including Pembrolizumab and Cisplatin, and has added specific facility locations in Japan. Additionally, the revision number has been updated to v3.0.0.
    Difference
    8%
    Check dated 2025-08-30T11:09:13.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in 1st Line NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in 1st Line NSCLC Clinical Trial page.